MAP3K8

Mitogen-activated protein kinase kinase kinase 8

11,530 patent compounds predicted against MAP3K8, 6,543 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2278592	1.00	20/20
SCHEMBL1225002	1.00	19/20
SCHEMBL2369872	1.00	19/20
SCHEMBL1225462	0.77	19/20
SCHEMBL1225822	0.76	19/20
SCHEMBL1224995	0.75	19/20
SCHEMBL1225787	0.73	19/20
SCHEMBL1225448	0.72	19/20
SCHEMBL1225433	0.69	19/20
SCHEMBL1225927	0.69	19/20
SCHEMBL1225429	0.68	19/20
SCHEMBL2278586	0.69	18/20
SCHEMBL1891925	0.73	16/20
SCHEMBL4036313	0.59	16/20
SCHEMBL1895770	0.58	16/20
SCHEMBL1895808	0.62	15/20
SCHEMBL2369875	1.00	14/20
SCHEMBL3193466	0.48	14/20
SCHEMBL3195945	0.45	14/20
SCHEMBL3596737	0.65	13/20

Germline variants in MAP3K8 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAP3K8 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAP3K8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer	PHASE3	RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS	PHASE2	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Biomarker Analysis of Gastrointestinal Cancer	nan	UNKNOWN
Histiocytic Disorder Follow-up Study	nan	RECRUITING
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP3K8 binder may also engage these)

Protein	Name	Similarity
Q63562	—	1.000	Q63562 →
Q07174	—	1.000	Q07174 →
B2GUY1	—	0.991	B2GUY1 →
Q5R667	—	0.990	Q5R667 →
Q924U5	—	0.990	Q924U5 →
Q9Z2R9	—	0.990	Q9Z2R9 →
Q7TNL3	—	0.989	Q7TNL3 →
Q9CAV6	—	0.989	Q9CAV6 →
Q7T0B1	—	0.989	Q7T0B1 →
Q17QV9	—	0.989	Q17QV9 →
Q641K5	—	0.989	Q641K5 →
Q8S8Y8	—	0.988	Q8S8Y8 →
Q7TNL4	—	0.988	Q7TNL4 →
Q6YY75	—	0.988	Q6YY75 →
Q8N2I9	—	0.988	Q8N2I9 →
G5EFD2	—	0.988	G5EFD2 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.988	landscape →
Q4R8E0	—	0.988	Q4R8E0 →
Q68UT7	—	0.987	Q68UT7 →
Q8RXT4	—	0.987	Q8RXT4 →
Q9UHY1	—	0.987	Q9UHY1 →
Q6XUX1	—	0.987	Q6XUX1 →
Q5R8X7	—	0.987	Q5R8X7 →
A7MBB4	—	0.987	A7MBB4 →
A7E379	—	0.987	A7E379 →
A2A3K4	—	0.987	A2A3K4 →
Q6DDJ5	—	0.986	Q6DDJ5 →
Q3ULB5	—	0.986	Q3ULB5 →
Q5ICL9	—	0.986	Q5ICL9 →
Q8WML3	—	0.986	Q8WML3 →